Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Monopar Therapeutics from “hold” to “sell,” although the broader analyst consensus remains “Moderate Buy” with a $122 price target.
• MNPR shares opened at $78.96 after falling 6%, well below their 50-day moving average of $104.34; the stock has traded between $50.07 and $124.82 over the past year.
• Insiders sold 44,688 shares worth approximately $4.02 million over the past three months, while institutional investors own only 1.83% of the company.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other research firms have also recently weighed in on MNPR. Barclays reaffirmed an "overweight" rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Cantor Fitzgerald cut Monopar Therapeutics from an "overweight" rating to a "neutral" rating and increased their price target for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a report on Thursday, July 23rd. HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.00.

Monopar Therapeutics Trading Down 6.0%

Shares of NASDAQ MNPR opened at $78.96 on Friday. The company has a market cap of $529.82 million, a price-to-earnings ratio of -36.39 and a beta of 1.50. Monopar Therapeutics has a 12 month low of $50.07 and a 12 month high of $124.82. The stock has a 50-day moving average price of $104.34 and a two-hundred day moving average price of $83.50.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. On average, sell-side analysts predict that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insider Buying and Selling at Monopar Therapeutics

In related news, Director Kim Tsuchimoto sold 4,090 shares of the business's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the sale, the director owned 7,396 shares of the company's stock, valued at $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the sale, the director owned 5,173 shares of the company's stock, valued at $406,080.50. The trade was a 61.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,688 shares of company stock worth $4,023,094 in the last three months. 9.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Monopar Therapeutics

A number of hedge funds have recently made changes to their positions in MNPR. Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth approximately $86,000. Your Advocates Ltd. LLP bought a new position in Monopar Therapeutics during the 1st quarter worth approximately $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics during the 1st quarter worth approximately $250,000. Sei Investments Co. lifted its position in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company's stock worth $415,000 after purchasing an additional 656 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter worth approximately $654,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company's research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar's portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.